Markedly increased IP-10 production by blood-brain barrier in neuromyelitis optica

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Shimizu, Fumitaka ^a   Nishihara, Hideaki ^a   Sano, Yasuteru ^a   Takeshita, Yukio ^a   Takahashi, Shiori ^a   Maeda, Toshihiko ^a   Takahashi, Toshiyuki ^b   Abe, Masaaki ^a   Koga, Michiaki ^a   Kanda, Takashi ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM ALBUMIN; CYTOKINE;

ACUTE PHASE RESPONSE; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; AUTOCRINE EFFECT; BLOOD BRAIN BARRIER; BRAIN LEVEL; CAPILLARY ENDOTHELIAL CELL; CELL MIGRATION; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOASSAY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PATHOGENESIS; PROTEIN FUNCTION; REMISSION; UPREGULATION; AGED; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; CELL LINE; ENDOTHELIUM CELL; METABOLISM; NEUROMYELITIS OPTICA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SERUM; SPINE;

ADULT; AGED; BLOOD-BRAIN BARRIER; CASE-CONTROL STUDIES; CELL LINE; CHEMOKINE CXCL10; CYTOKINES; ENDOTHELIAL CELLS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; SERUM; SPINE;

EID: 84926366494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122000     Document Type: Article

References (37)

1. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489. PMID: 16717206
2. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815. PMID: 17706564
3. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112. PMID: 15589308
4. Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007; 69: 2221-2231. PMID: 17928579
5. Vincent T, Saikali P, Cayrol R, Roth AD, Bar-Or A, Prat A, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008; 181: 5730-5737. PMID: 18832732
6. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012; 11: 535-544. doi: 10.1016/S1474-4422(12)70133-3 PMID: 22608667
7. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009; 66: 630-643. doi: 10.1002/ana.21837 PMID: 19937948
8. Sharma R, Fischer MT, Bauer J, Felts PA, Smith KJ, Misu T, et al. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol 2010; 120: 223-236. doi: 10.1007/s00401-010-0704-z PMID: 20532539
9. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010; 133: 349-361. doi: 10.1093/brain/awp309 PMID: 20047900
10. Pohl M, Kawakami N, Kitic M, Bauer J, Martins R, Fischer MT, et al. T cell-activation in neuromyelitis optica lesions plays a role in their formation. Acta Neuropathol Commun 2013; 1: 85. doi: 10.1186/2051-5960-1-85 PMID: 24367907
11. Kitic M, Hochmeister S, Wimmer I, Bauer J, Misu T, Mader S, et al. Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats. Acta Neuropathol Commun 2013; 1:5. doi: 10.1186/2051-5960-1-5 PMID: 24252536
12. Uzawa A, Mori M, Masuda S, Kuwabara S. Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica. Arch Neurol 2011; 68: 913-917. doi: 10.1001/archneurol.2011.148 PMID: 21747031
13. Uzawa A, Mori M, Kuwabara S. Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications. Brain Pathol 2014; 24: 67-73. doi: 10.1111/bpa.12097 PMID: 24345220
14. Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One 2013; 8: e61835. doi: 10.1371/journal.pone.0061835 PMID: 23637915
15. Içöz S, Tüzün E, Kürtüncü M, Durmuş H, Mutlu M, Eraksoy M, et al. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci 2010; 120: 71-75. doi: 10.3109/00207450903428970 PMID: 20128675
16. Uzawa A, Mori M, Sawai S, Masuda S, Muto M, Uchida T, et al. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta 2013; 421: 181-183. doi: 10.1016/j.cca.2013.03.020 PMID: 23535508
17. Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 2010; 16: 1443-1452. doi: 10.1177/1352458510379247 PMID: 20739337
18. Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007; 130: 1224-1234. PMID: 17405762
19. Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol 2014; 24: 83-97. doi: 10.1111/bpa.12099 PMID: 24345222
20. Shimizu F, Sano Y, Takahashi T, Haruki H, Saito K, Koga M, et al. Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J Neurol Neurosurg Psychiatry 2012; 83: 288-297. doi: 10.1136/jnnp-2011-300434 PMID: 22100760
21. Tasaki A, Shimizu F, Sano Y, Fujisawa M, Takahashi T, Haruki H, et al. Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2014; 85: 419-430. doi: 10.1136/jnnp-2013-305907 PMID: 24259591
22. Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007; 130: 1235-1243. PMID: 17449477
23. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302. doi: 10.1002/ana.22366 PMID: 21387374
24. Sano Y, Shimizu F, Abe M, Maeda T, Kashiwamura Y, Ohtsuki S, et al. Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J Cell Physiol 2010; 225: 519-528. doi: 10.1002/jcp.22232 PMID: 20458752
25. Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, Takakura Y, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005; 128: 988-1002. PMID: 15743872
26. Yanagawa K, Kawachi I, Toyoshima Y, Yokoseki A, Arakawa M, Hasegawa A, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 2009; 73: 1628-1637. doi: 10.1212/WNL.0b013e3181c1deb9 PMID: 19917985
27. Narikawa K, Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2004; 149: 182-186. PMID: 15020078
28. Szczuciński A, Losy J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand 2007; 115: 137-146. PMID: 17295707
29. Fife BT, Kennedy KJ, Paniagua MC, Lukacs NW, Kunkel SL, Luster AD, et al. CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 2001; 166: 7617-7624. PMID: 11390519
30. Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, Shats I, et al. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 2005; 115: 2731-2741. PMID: 16184194
31. Haruki H, Sano Y, Shimizu F, Omoto M, Tasaki A, Oishi M, et al. NMO sera down-regulate AQP4 in human astrocyte and induce cytotoxicity independent of complement. J Neurol Sci 2013; 331: 136-144. doi: 10.1016/j.jns.2013.05.035 PMID: 23809190
32. Kieseier BC, Stüve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 2013; 70: 390-393. PMID: 23599943
33. Ayzenberg I, Kleiter I, Schröder A, Hellwig K, Chan A, Yamamura T, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013; 70: 394-397. doi: 10.1001/jamaneurol.2013.1246 PMID: 23358868
34. Shimizu F, Kanda T. The Blood-Brain Barrier in Neuroinflammation. In Suzumura A, Ikenaka K, editors. Neuron-Glia Interaction in Neuroinflammation. New York, NY: Springer Science+Business Media New York 2013; pp. 157-179.
35. Alvarez JI, Cayrol R, Prat A. Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta 2011; 1812: 252-264. doi: 10.1016/j.bbadis.2010.06.017 PMID: 20619340
36. Thompson CD, Zurko JC, Hanna BF, Hellenbrand DJ, Hanna A. The therapeutic role of interleukin-10 after spinal cord injury. J Neurotrauma 2013; 30: 1311-1324. doi: 10.1089/neu.2012.2651 PMID: 23731227
37. Shimizu F, Tasaki A, Sano Y, Ju M, Nishihara H, Oishi M, et al. Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier. PLoS One 2014; 9: e92872. doi: 10.1371/journal.pone.0092872 PMID: 24686948